Brought to you by 
Coley grants VaxImmune license to Merck
03 May 2007
Executive Summary
Coley Pharmaceutical (develops immune system modulators) has granted Merck worldwide nonexclusive rights to use its VaxImmune vaccine adjuvant in the development of infectious and Alzheimer's disease preventatives.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Coley grants VaxImmune license to Merck
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice